De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Ardelyx Toekomstige groei
Future criteriumcontroles 6/6
Ardelyx zal naar verwachting groeien in winst en omzet met respectievelijk 66.4% en 27.2% per jaar. De winst per aandeel zal naar verwachting groeien met 66.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 49.2% zijn.
Belangrijke informatie
66.4%
Groei van de winst
66.4%
Groei van de winst per aandeel
| Biotechs winstgroei | 28.8% |
| Inkomstengroei | 27.2% |
| Toekomstig rendement op eigen vermogen | 49.2% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 03 Oct 2024 |
Recente toekomstige groei-updates
Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04
Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Recent updates
Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Aug 25Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 07Ardelyx Faces Rising Challenges Despite Revenue Growth
Aug 05Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Jul 13Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
Jul 05Ardelyx: Strong Execution, Fairly Valued
May 10Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)
May 03Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 03Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
Jul 31Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now
Apr 17Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Mar 30Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Dec 14What To Expect For Ardelyx In The Coming Month
Oct 18Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position
Oct 04Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale
Jun 30Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 557 | 119 | 167 | 163 | 9 |
| 12/31/2025 | 404 | -24 | -15 | 45 | 10 |
| 12/31/2024 | 306 | -59 | N/A | 8 | 10 |
| 6/30/2024 | 210 | -65 | -86 | -85 | N/A |
| 3/31/2024 | 159 | -66 | -81 | -81 | N/A |
| 12/31/2023 | 124 | -66 | -90 | -90 | N/A |
| 9/30/2023 | 134 | -27 | -67 | -67 | N/A |
| 6/30/2023 | 83 | -56 | -71 | -71 | N/A |
| 3/31/2023 | 63 | -66 | -87 | -87 | N/A |
| 12/31/2022 | 52 | -67 | -70 | -70 | N/A |
| 9/30/2022 | 9 | -114 | -124 | -124 | N/A |
| 6/30/2022 | 5 | -135 | -133 | -133 | N/A |
| 3/31/2022 | 4 | -153 | -137 | -136 | N/A |
| 12/31/2021 | 10 | -158 | -154 | -153 | N/A |
| 9/30/2021 | 11 | -151 | -133 | -131 | N/A |
| 6/30/2021 | 12 | -125 | -118 | -116 | N/A |
| 3/31/2021 | 13 | -105 | -102 | -101 | N/A |
| 12/31/2020 | 8 | -94 | -82 | -81 | N/A |
| 9/30/2020 | 8 | -85 | -75 | -75 | N/A |
| 6/30/2020 | 8 | -91 | -76 | -76 | N/A |
| 3/31/2020 | 6 | -91 | -85 | -85 | N/A |
| 12/31/2019 | 5 | -95 | -77 | -76 | N/A |
| 9/30/2019 | 3 | -103 | -84 | -84 | N/A |
| 6/30/2019 | 0 | -104 | -91 | -90 | N/A |
| 3/31/2019 | 0 | -100 | -81 | -80 | N/A |
| 12/31/2018 | 3 | -91 | -71 | -70 | N/A |
| 9/30/2018 | 45 | -53 | -47 | -47 | N/A |
| 6/30/2018 | 44 | -50 | -40 | -39 | N/A |
| 3/31/2018 | 44 | -53 | N/A | -45 | N/A |
| 12/31/2017 | 42 | -64 | N/A | -65 | N/A |
| 9/30/2017 | N/A | -106 | N/A | -97 | N/A |
| 6/30/2017 | N/A | -114 | N/A | -102 | N/A |
| 3/31/2017 | N/A | -117 | N/A | -103 | N/A |
| 12/31/2016 | N/A | -112 | N/A | -93 | N/A |
| 9/30/2016 | N/A | -98 | N/A | -87 | N/A |
| 6/30/2016 | N/A | -87 | N/A | -75 | N/A |
| 3/31/2016 | 18 | -50 | N/A | -80 | N/A |
| 12/31/2015 | 24 | -30 | N/A | -72 | N/A |
| 9/30/2015 | 30 | -16 | N/A | -54 | N/A |
| 6/30/2015 | 38 | 2 | N/A | -48 | N/A |
| 3/31/2015 | 29 | -6 | N/A | 6 | N/A |
| 12/31/2014 | 32 | -3 | N/A | 13 | N/A |
| 9/30/2014 | 34 | -4 | N/A | 28 | N/A |
| 6/30/2014 | 33 | -5 | N/A | 34 | N/A |
| 3/31/2014 | 31 | -7 | N/A | 5 | N/A |
| 12/31/2013 | 29 | -7 | N/A | 2 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat ARDX de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.5% ).
Winst versus markt: Er wordt verwacht dat ARDX de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat ARDX binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van ARDX ( 27.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van ARDX ( 27.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ARDX zal naar verwachting over 3 jaar zeer hoog zijn ( 49.2 %).